A view from SOHO UK: navigating the challenges and complexity of haematology
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to
Charles Craddock, CBE, FRCP, FRCPath, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares ASH 2025
Invivoscribe has announced the launch of its newly developed test for leukemia diagnostics, the LeukoStrat® KMT2A + MRD Assay, specifically for patients with
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in
The second session of the Community Oncology Brown Bag Series hosted by SOHO Insider featured guest speaker Tara Graff, DO, an oncologist at
Bor-Sheng Ko, MD, PhD, Associate Professor at National Taiwan University College of Medicine and President of the Hematology Society of Taiwan, discusses the
In this video interview from SOHO Asia, Dr. Wang, MD, PhD, consultant hematologist at National Taiwan University Cancer Center, discusses the current unmet
The US Food and Drug Administration (FDA) approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta), removing the previous Limitations of